NASDAQ: DXCM · Medical Devices
DexCom (DXCM) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values DexCom (DXCM) at $73.84 a share. The stock last closed at $81.61, which puts the model's fair value 9.5% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. DexCom, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $70.82 to $73.84 (+4.3%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $81.61 is 9.5% above it: Fairly valued, on a medium evidence grade.
What's nextNext report on 11 Feb 2027. Options prices imply a move of about 12% either way over the next month. On the model's Quality Momentum list since 30 Oct 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give DXCM?
The calibrated range for DXCM over 63 trading days is $71.52 to $93.74. It sits around the last close, and its width comes from the volatility that DXCM's own options imply (40% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $53.03 to $101.25. In 38% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems.
Faircurve's model put the fair value at $73.84 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $70.82, so the fair value moved +4.3%. The model says: "The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move." The calibrated range over 63 trading days is $73.71 to $94.79, built from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium, based on input completeness, the number and agreement of comparable companies, and the width of outcomes. It does not say whether the fair value is right.
The model's overall quality score is 73 out of 100, against comparable companies. Profitability scores 95, with ROIC of 32.4% against a peer median of 11.9%. Stability scores 30, with five-year EBITDA margin downside volatility of 3.5 pts against a peer median of 1.4 pts. The model compares DexCom with GE HealthCare Technologies Inc. (GEHC), Zimmer Biomet Holdings, Inc. (ZBH), Edwards Lifesciences Corporation (EW), Boston Scientific Corporation (BSX), Penumbra, Inc. (PEN), Align Technology, Inc. (ALGN) and Insulet Corp. (PODD).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does DXCM report earnings, and how has the stock reacted?
DexCom's next earnings report is scheduled for 11 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 5.3% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. DXCM's 30 day implied volatility works out to about 11.5% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across DXCM's last 8 reports, ignoring direction, was 8.1%.
What the options market has priced for a month's move in DXCM
How does DXCM score on business quality?
DexCom's overall quality score is 73 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 95 | 32.4%ROIC | 11.9% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 55 | 1.11xFCF / net income | 1.19x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 83 | 15.6%Revenue growth, trailing | 8.5% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 60 | 4.2%Net buybacks / market value | 1.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 79 | 0.28xNet debt / EBITDA | 0.63x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 30 | 3.5 ptsEBITDA margin downside volatility, 5y | 1.4 pts |
How does DXCM compare with similar companies?
The companies in medical devices closest to DexCom in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| GEHC GE HealthCare Technologies Inc. | $82.96 | $90.14 | +8.7% | Fairly valued |
| ZBH Zimmer Biomet Holdings, Inc. | $101.41 | $120.99 | +19.3% | Undervalued |
| EW Edwards Lifesciences Corporation | $107.11 | $88.12 | -17.7% | Overvalued |
| BSX Boston Scientific Corporation | $43.69 | $52.05 | +19.1% | Undervalued |
| GKOS Glaukos Corporation | $244.88 | $228.07 | -6.9% | Data under review |
| PEN Penumbra, Inc. | $320.62 | $296.43 | -7.5% | Fairly valued |
| ALGN Align Technology, Inc. | $165.98 | $200.67 | +20.9% | Undervalued |
| PODD Insulet Corp. | $145.29 | $158.48 | +9.1% | Fairly valued |
What the comparable companies' multiples alone would give for DXCM, the peer-implied price, is $61.10 a share on this run. The fair value weighs that against the company's own multiple.
DexCom at a glance
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems.
- Market value
- $31.1B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $5.7B
- Consensus revenue growth, next fiscal year
- +12.2%
- Analysts with estimates
- 15
- Beta to the US market
- 0.68
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. DXCM was not among them.
How the fair value is worked out: the model prices DexCom on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for DXCM was $70.82. As of 14 Nov 2026 it is $73.84, a change of +4.3%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about DexCom's valuation
Is DexCom stock undervalued or overvalued?
On Faircurve's model, DXCM reads as Fairly valued as of 14 Nov 2026. The model's fair value is $73.84 a share against a last close of $81.61, a gap of -9.5%.
What is DXCM's fair value?
$73.84 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $53.03 to $101.25.
What price range does the model give DXCM?
$71.52 to $93.74 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does DexCom report earnings next?
The next report is scheduled for 11 Feb 2027. Companies can move their dates.
How much has DXCM moved on past earnings reports?
Across its last 8 reports the median two session move was 8.1%, ignoring direction. The largest was -14.6% around the report of 30 Oct 2025.
How confident is the model in this valuation?
The model's evidence grade for DXCM is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on DXCM
The model has an idea open on DXCM under Quality Momentum since 30 Oct 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on DXCM with their outcomes. A free account is enough.